Reckitt Benckiser: Spinning off pharma division a strong option

Reckitt Benckiser (RBGLY) could spin off its declining pharmaceuticals operations, saying that the idea is "emerging as a strong option." However, selling the business or even keeping it are still possible.

The division's net sales dropped 15% in Q1 to £170M.

Total net revenues declined 6% to £2.37B.

Shares are +0.3% in London. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs